What this deck covers
This deck focuses on Dosage Forms And Routes, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Dosage Forms And Routes in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
What does the abbreviation DR indicate for an oral solid dosage form?
Tap card or press Space to flip
Delayed-release; release occurs later (often enteric). Refers to formulations that delay drug release until reaching a specific site, protecting against gastric degradation.
How well did you know it?
Card 1 / 25
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Dosage Forms And Routes, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: Delayed-release; release occurs later (often enteric). Refers to formulations that delay drug release until reaching a specific site, protecting against gastric degradation.
Answer: Swallow whole; do not crush, chew, or split. Preserves coating integrity to ensure delayed release in intestine, preventing premature drug exposure.
Answer: Otic route. Direct instillation into ear canal targets local inflammation or infection without widespread distribution.
Answer: Cream. Oil-in-water composition provides moisturizing effects with lighter texture, suitable for acute dermatoses.
Answer: Subcutaneous (SC). Injection into subcutaneous tissue allows gradual absorption, suitable for medications requiring sustained release.
Answer: MDI. MDIs benefit from spacers to coordinate inhalation, unlike DPIs which are activated by breath alone.
Answer: Place under tongue and allow to dissolve; do not swallow. Allows rapid absorption through sublingual mucosa, bypassing gastrointestinal tract and first-pass metabolism.
Answer: Intranasal route. Nasal mucosa allows rapid absorption for both decongestant effects and potential systemic delivery.
Answer: Place between gum and cheek and allow to dissolve. Enables drug absorption via buccal mucosa, providing an alternative to oral ingestion for better bioavailability.
Answer: Orally disintegrating tablet (ODT). Formulated for rapid disintegration on the tongue, facilitating administration for patients with swallowing difficulties.
Answer: Intrathecal (IT). Direct delivery to cerebrospinal fluid bypasses blood-brain barrier for targeted central nervous system effects.
Answer: Ophthalmic (topical ocular) route. Topical application to eye ensures high local concentration with minimal systemic absorption.
Answer: Prevent gastric release; dissolve in higher intestinal pH. Coating resists acidic stomach environment, ensuring drug release in alkaline intestine to avoid irritation or inactivation.
Answer: Inhalation (pulmonary) route. Delivers medication directly to respiratory tract for rapid local action on pulmonary tissues.
Answer: Immediate systemic effect; 100% bioavailability. Direct injection into bloodstream ensures complete and rapid drug availability without absorption barriers.
Answer: Extended-release; prolonged drug release over time. Denotes formulations designed to release drug gradually, extending therapeutic effects and reducing dosing frequency.
Answer: Gel. Semisolid hydrogel matrix offers cooling sensation and easy spreading without residue on application.
Answer: Sublingual. Absorption through sublingual mucosa delivers drug directly into systemic circulation, avoiding hepatic metabolism.
Answer: Improve lung deposition and reduce oropharyngeal deposition. Spacer slows aerosol velocity, allowing better timing of inhalation and minimizing drug loss in the mouth.
Answer: MDI is propellant-driven; DPI is breath-actuated powder. MDI uses pressurized gas to disperse liquid, while DPI relies on patient's inhalation to aerosolize dry powder.
Answer: Sustained systemic delivery and avoidance of first-pass metabolism. Transdermal delivery maintains steady plasma levels and circumvents hepatic first-pass, improving efficacy.
Answer: Intramuscular (IM). Injection into muscle provides a reservoir for slow release, ideal for long-acting formulations.
Answer: Immediate-release; no modified-release mechanism. Indicates standard formulation where drug is released promptly upon administration without mechanisms to alter release rate.
Answer: Ointment. High lipid content creates a barrier that enhances hydration and drug penetration on dry skin.
Answer: Suppository. Base melts at 37°C, releasing drug for local or systemic absorption via rectal mucosa.